These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6629211)

  • 1. [General pharmacology of traxanox sodium. I. Effects on the central, somatic, and autonomic nervous systems, digestive system, urologic organs, and reproductive system].
    Goto K; Osuga K; Haga K; Tsumagari T
    Nihon Yakurigaku Zasshi; 1983 May; 81(5):343-63. PubMed ID: 6629211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General pharmacological properties of the main metabolite of flosequinan.
    Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
    Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
    Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
    Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
    Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General pharmacology of the new quinolone antibacterial agent levofloxacin.
    Takasuna K; Kasai Y; Usui C; Takahashi M; Hirohashi M; Tamura K; Takayama S
    Arzneimittelforschung; 1992 Mar; 43(3A):408-18. PubMed ID: 1622443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
    Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
    Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 2nd communication: effect on the peripheral nervous system and peripheral organs.
    Hirotsu I; Kihara T; Hattori Y; Hatta M; Hirose N; Ishihara T; Satoh F
    Arzneimittelforschung; 1988 Oct; 38(10):1410-7. PubMed ID: 3196381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological studies on timiperone, a new neuroleptic drug Part II: General pharmacological properties.
    Yamasaki T; Kojima H; Tanaka M; Aibara S; Hirohashi M; Kasai Y; Tsubokawa M; Watanabe K; Akashi A
    Arzneimittelforschung; 1981; 31(4):707-15. PubMed ID: 6113834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [General pharmacological actions of traxanox sodium. II. Effects on the cardiovascular system].
    Nakamura T; Miura Y; Aihara K; Satoh H; Goto K; Tsumagari T
    Nihon Yakurigaku Zasshi; 1983 Jul; 82(1):79-92. PubMed ID: 6137441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
    Murata T; Murai T; Kanai T; Ogaki Y; Sanai K; Kanda H; Sato S; Kajikawa N; Umetsu T; Matsuura H
    Arzneimittelforschung; 1989 Aug; 39(8):867-76. PubMed ID: 2510743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle.
    Arisawa H; Fukui K; Fujise N; Masunaga H
    Arzneimittelforschung; 2002; 52(2):81-8. PubMed ID: 11878203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G; Morimoto S; Shiomi M
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological studies on oxatomide: (6) Effect on the peripheral organs].
    Ohmori K; Ishii H; Shuto K; Nakamizo N
    Nihon Yakurigaku Zasshi; 1983 Jan; 81(1):79-104. PubMed ID: 6133821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [[Effect of traxanox sodium on type I-IV allergic reactions. Studies on anti-allergic agents VII].
    Terasawa M; Goto K; Maruyama Y
    Nihon Yakurigaku Zasshi; 1982 Dec; 80(6):417-27. PubMed ID: 6219052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [General pharmacological studies on isepamicin sulfate (HAPA-B)].
    Shibata K; Mita I; Shinoda Y; Nakano U; Kinoshita H; Noguchi M; Uzawa T; Sohmiya Y; Takayanagi N
    Jpn J Antibiot; 1987 Jan; 40(1):145-69. PubMed ID: 3586327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [General pharmacology of 6-amino-2-fluoromethyl-3-(o-tolyl)-4(3H)-quinazolinone (afloqualone), a new centrally acting muscle relaxant. II. Effects on the peripheral system (author's transl)].
    Ochiai T; Fukuchi I; Ego H; Yamamura M; Kudo Y; Ishida R
    Nihon Yakurigaku Zasshi; 1981 Oct; 78(4):359-80. PubMed ID: 7327456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
    Matsuno Y; Taira N; Fujitani B; Ito T; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.